NexgenRx Third Quarter 2024 Earnings: EPS: CA$0.002 (vs CA$0.002 loss in 3Q 2023)

Simply Wall St · 5d ago

NexgenRx (CVE:NXG) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CA$4.16m (up 23% from 3Q 2023).
  • Net income: CA$149.2k (up from CA$130.7k loss in 3Q 2023).
  • Profit margin: 3.6% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.
  • EPS: CA$0.002 (up from CA$0.002 loss in 3Q 2023).
earnings-and-revenue-history
TSXV:NXG Earnings and Revenue History November 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

NexgenRx shares are down 1.7% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for NexgenRx (2 don't sit too well with us!) that you should be aware of.